Evidence map›Paper›PMID 41145955›Full record

ArticleMedical physics2025

In silico assessment of cellular damage from Lu-177, Ac-225, and Pb-212 therapeutic radionuclides.

Konstantinos P Chatzipapas, Konstantinos Papachristou, Dimitris Visvikis, Sebastien Incerti, John D Hazle, George C Kagadis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Konstantinos P ChatzipapasDepartment of Radiation Science and Technology, Delft University of Technology, Delft, Netherlands.
Konstantinos Papachristou3DMI Research Group, Department of Medical Physics, School of Medicine, University of Patras, Rion, Greece.
Dimitris VisvikisLaboratoire de Traitement de l'Information Médicale (LaTIM), UMR 1101, INSERM, University of Brest, Brest, France.
Sebastien IncertiLaboratoire de Physique des 2 infinis de Bordeaux (LP2IB), UMR 5797, CNRS, University of Bordeaux, Gradignan, France.
John D HazleDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
George C Kagadis3DMI Research Group, Department of Medical Physics, School of Medicine, University of Patras, Rion, Greece.ORCID https://orcid.org/0000-0002-6983-2863

Funding

Dutch Ministry of Economic Affairs 1300033255European Union's EURATOM research and innovation program 101061037Hellenic Foundation for Research and Innovation (H.F.R.I.) 2692
6 · The paper itself

Abstract

backgroundTargeted radionuclide therapy (TRT) has emerged as a unique and effective treatment modality for cancer. Monte Carlo simulations have greatly advanced investigations into radiation-caused DNA damage, including the complexity of this damage. PURPOSE: This study aimed to evaluate DNA damage induced by high-linear energy transfer therapeutic radionuclides used in TRT, specifically

methodsThe Geant4-DNA toolkit, incorporating the "molecularDNA" example, was employed to simulate radiation interactions within a human fibroblast cell model featuring a fractal chromatin fiber geometry within an ellipsoidal nucleus. Three source geometries (membrane, cytoplasm, nucleus) were modeled to assess the impact of radionuclide localization. Key metrics, including absorbed dose, double-strand break (DSB) yield, single-strand break/DSB ratio, and DSB/Gbp/decay, were calculated for

resultsAlpha emitter

conclusionsGeant4-DNA simulations highlight the superior radiobiological effectiveness of alpha emitters, particularly

Indexed as

ActiniumComputer SimulationDNA DamageLead RadioisotopesLutetiumRadioisotopesDNA Breaks, Double-StrandedFibroblastsHumansMonte Carlo MethodActiniumActinium-225Lead RadioisotopesLutetiumLutetium-177RadioisotopesdosimetryGeant4‐DNAmolecular radiotherapyMonte Carlo simulationsradionuclide therapy

Identifiers

PMID41145955
PMCPMC12559466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.